Late Relapse of Diffuse Large B-Cell Lymphoma in a Patient with Minor Thalassemia: A Diagnostic Challenge
DOI:
https://doi.org/10.19166/med.v15i3.11447Keywords:
DLBCL, late relapse, minor thalassemia, diagnostic challengesAbstract
Background:
Diffuse large B-cell lymphoma (DLBCL) commonly responds to chemoimmunotherapy, and relapse risk usually decreases after prolonged remission. Thalassemia has been associated with increased risk of hematologic malignancy, although its relationship with late DLBCL relapse remains unclear.
Case Description:
A 68-year-old woman with minor thalassemia and a history of primary mediastinal B-cell lymphoma in complete remission for 15 years presented with fever and fatigue. Laboratory findings showed pancytopenia and elevated lactate dehydrogenase. FDG-PET/CT demonstrated increased uptake in the spleen and bone marrow. Bone marrow biopsy showed large B-lymphoid cells positive for CD20 and MUM1, establishing relapsed DLBCL with extranodal involvement. Complete remission was achieved after two cycles of R-COP chemotherapy, but the patient later died from severe infection, metabolic complications, and cardiomyopathy during the fourth cycle.
Conclusions:
Late relapse of DLBCL in patients with thalassemia is diagnostically challenging because cytopenia and systemic symptoms may overlap with hematologic complications. Long-term surveillance and prompt evaluation of new pancytopenia, splenomegaly, or systemic symptoms are essential in lymphoma survivors with thalassemia.
References
1. Padala SA, Kallam A. Diffuse large B-cell lymphoma. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557796/
2. Berhan, A., Almaw, A., Damtie, S. et al. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Onc 16, 184 (2025). https://doi.org/10.1007/s12672-025-01958-w
3. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–58. doi:10.1056/NEJMra2027612.
4. Bajwa H, Basit H. Thalassemia. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545151/
5. National Cancer Institute. SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma (DLBCL). Bethesda (MD): U.S. National Institutes of Health; [cited 2025 Oct 21]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html
6. Basso K. Biology of germinal center B cells relating to lymphomagenesis. HemaSphere. 2021;5(6):e582. doi:10.1097/HS9.0000000000000582.
7. Vodicka P, Klener P, Trneny M. Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options. Onco Targets Ther. 2022;15:1481–501. doi:10.2147/OTT.S326632.
8. Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):15–25.
9. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–16.
10. Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Fend L, editors. Hematopathology. 4th ed. Philadelphia: Elsevier; 2016. Chapter: Diffuse large B-cell lymphoma.
11. Sehn LH, Salles G. Diffuse large B-cell lymphoma. Nat Rev Clin Oncol. 2021;18(11):727–47. doi:10.1038/s41571-021-00538-4.
12. Schmitz R, Wright GW, Huang DW, et al. Genetic subtypes of diffuse large B-cell lymphoma determined by gene expression and mutations. N Engl J Med. 2018;378(15):1396–407. doi:10.1056/NEJMoa1801445.
13. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368–76.
14. Jin J, Ji D, Xia Z, Xue K, Zhang Q, Liu Y, et al. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. BMC Cancer. 2022;22:403. doi:10.1186/s12885-022-09486-4.
15. Nowakowski GS, Johnston PB, Cerhan JR, Habermann TM, Witzig TE, Ansell SM, et al. Outcomes in patients with late relapse of diffuse large B-cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2025;doi:10.1016/j.jtct.2025.06.041.
16. Weiss J, Carty SA, Karimi YH. Molecular pathways and targeted therapies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Cancers (Basel). 2025;17(14):2314. doi:10.3390/cancers17142314.
17. Shaw J, Chakraborty A, Nag A, Chattopadhyay A, Dasgupta AK, Bhattacharyya M. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. Eur J Haematol. 2017;99(4):399-408. doi:10.1111/ejh.12936.
18. Palomo-Colli MA, Zapata-Tarres M, Castelán-Martínez OD, Juárez-Villegas LE, Córdova-Hurtado LP. A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of β-thalassemia major: a case report. Mol Clin Oncol. 2018;8(2):375–7. doi:10.3892/mco.2017.1533.
19. Hodroj MH, Bou-Fakhredin R, Nour-Eldine W, Noureldine HA, Noureldine MHA, Taher AT. Thalassemia and malignancy: an emerging concern? Blood Rev. 2019;37:100585. doi:10.1016/j.blre.2019.06.002.
20. Cappellini M D, Motta I. New therapeutic targets in transfusion-dependent and non–transfusion-dependent thalassemia. Hematology Am Soc Hematol Educ Program. 2017;2017(1):278-285. doi: 10.1182/asheducation-2017.1.278.
21. Goh SC, Ngai S. The clinical challenge of relapsed diffuse large B-cell lymphoma with disseminated infection. Radiol Case Rep. 2023 Jun 22;18(9):3046-3053. doi: 10.1016/j.radcr.2023.05.068. PMID: 37434620; PMCID: PMC10331012.
22. Abdel-Hakeem SS, Ahmed AM, Amine MAF, Farouk BR, Yassin EH, Badary FAM. Clinicopathological features of relapsed diffuse large B-cell lymphoma: South Egypt Cancer Institute experience. SECI Oncology Journal. 2021;9(4):192-197. doi:10.21608/secioj.2021.194488.
23. Alavi S, Safari A, Sadeghi E, Amiri S. Hematological malignancies complicating β-thalassemia syndromes: a single-center experience. Blood Res. 2013;48(2):149–51. doi:10.5045/br.2013.48.2.149.
24. García-Sancho AM, Cabero A, Gutiérrez NC. Treatment of relapsed or refractory diffuse large B-cell lymphoma: new approved options. J Clin Med. 2023;13(1):70. doi:10.3390/jcm13010070.
25. Shi Y, Xu Y, Shen H, Jin J, Tong H, Xie W. Advances in biology, diagnosis and treatment of DLBCL. Ann Hematol. 2024;103(9):3315–33. doi:10.1007/s00277-024-05880-z.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Stephanie Marisca, Jennifer Jesse Limanto
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
